Key Drivers
- High Margins
- Strong Liquidity
- Rising Leverage
AIAI Summary
MIRM is now a commercial rare-disease story, but the investment case hinges on whether its raised 2026 sales outlook can finally outpace a rising cost base and $760M debt load; until revenue growth translates into narrower losses and the stock reclaims 94-95 support, the thesis remains execution- and leverage-driven rather than de-risked.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Margins
- •Strong Liquidity
- •Rising Leverage
MIRM shows strong gross margins and liquidity, but worsening losses, high expenses, and rising leverage are eroding profitability and balance-sheet quality.
Price Behavior
Key Price Behavior Insights:
- •Mid-$90s support
- •$100 test
- •Lower-high pressure
MIRM remains in a downtrend after falling about 15% over the last month from $118.86 to $100.64, but the bounce off $94.12 shows buyers are defending the mid-$90s while $100 and $104-$106 remain the key near-term tests.
Sharp drop from $118.86 to $100.64 with a rebound off $94.12 suggests a recovery attempt, not a confirmed uptrend
Sentiment & News
Key News Insights:
- •Guidance Raise
- •Livmarli Growth
- •Pipeline Catalysts
Mirum delivered a mixed Q2 with a revenue beat and raised 2026 sales guidance to $680M-$700M, highlighting strong Livmarli-led growth despite an earnings miss.
The higher sales outlook and solid product momentum are supportive for the stock, but the EPS miss may cap near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings